Strativa Pharmaceuticals’ Zuplenz NDA: FDA issues complete response letter

Strativa Pharmaceuticals announced today that the U.S. Food and Administration (FDA) issued a complete response letter regarding the new application (NDA) for Zuplenz® (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and .


Read more

Related posts

Leave a Reply